Redx Pharma plc - First RXC006 data for treatment of fibrosis
("Redx" or "the Company")
First RXC006 data suggests it has great potential for the treatment of fibrosis
First-in-man studies earmarked for 2020
In the first public disclosure of data on RXC006, Dr
More specifically, it was shown that RXC006 was able to suppress the release of Wnt-5a (another protein on the Wnt pathway) from human lung fibroblasts at nanomolar concentrations and reduce fibroblast activation. In two separate mouse models of disease, RXC006 strongly reduced collagen deposition and significantly impacted Ashcroft scores (a validated scale for estimating the severity of pulmonary fibrosis), when dosed therapeutically.
Dr Jörg Distler, Professor of Internal Medicine,
There is strong scientific evidence that the Wnt pathway is critically involved in the scarring process (fibrosis) in the lung that is the hallmark of IPF.1 Over time, this leads to the lungs being unable to function effectively, ultimately resulting in suffocation and death. RXC006 represents a novel approach to treat this debilitating and progressive disease through targeting porcupine, a component enzyme of the Wnt pathway. Porcupine inhibition suppresses the release of all Wnt ligands and therefore should eliminate one of the major drivers of fibrosis in IPF. The median survival from IPF diagnosis is 3 years and the annual incidence is between 6.8-16.3/100,000 population in the
The poster presentation is available via this link here: RXC006 AFDD Meeting Poster.
For further information, please contact:
| || |
T: +44 1625 469 920
| || |
| || |
T: +44 20 7894 7000
| || |
| || |
T: +44 20 3705 9330
T: +44 20 3727 1000
| || |
Redx is a
If you would like to sign up to regular alerts from
IPF is a life threatening fibrotic lung condition with diagnosed prevalence projected to increase from 119,000 (2015) to 138,000 (2025). Current treatment options are OFEV®(nintedanib) and Esbriet® (pirfenidone); both slow progression of disease by approximately 50%. Product sales in IPF are projected to increase from
Redx has invested into research to target the Wnt /ß-Catenin signalling pathway by inhibition of the upstream porcupine enzyme and has built considerable knowledge and expertise in this scientific area. Our most advanced porcupine inhibitor, RXC004, is currently being investigated clinically for the treatment of a range of cancers. RXC006 is a potent porcupine inhibitor protected by discrete Intellectual Property and has a predicted human PK profile which will allow flexibility in dosing regimens to balance efficacy with potential side effects. RXC006 is the first porcupine inhibitor aimed at treating IPF.
1. Newman DR, Sills WS, Hanrahan K, Ziegler A, Tidd KM, Cook E, Sannes PL.
Expression of WNT5A in Idiopathic Pulmonary Fibrosis and Its Control by TGF-β and WNT7B in Human Lung Fibroblasts. J Histochem Cytochem. 2016 Feb;64(2):99-111.
2. Global Data Opportunity Analyser 2015, based on 7 major markets
This information is provided by RNS, the news service of the
Quick facts: Redx Pharma PLC
Market Cap: £122.42 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...FOR OUR FULL DISCLAIMER CLICK HERE